Pancreatic beta-cell insulin secretion machinery

The pancreatic beta-cell insulin secretion machinery is a complex integrated system responsible for the synthesis, storage, and regulated release of insulin in response to physiological stimuli, primarily glucose (StatPearls, PMID: 30422492). The core process, known as glucose-stimulated insulin secretion (GSIS), involves glucose uptake via transporters (GLUT1/GLUT2), metabolic generation of ATP, and the subsequent closure of ATP-sensitive potassium (K_ATP) channels (PubMed, PMID: 28434033). This leads to membrane depolarization, activation of voltage-gated calcium channels, and a calcium-triggered exocytotic burst of insulin granules (NIH, Gene ID: 3630). Beyond glucose, the machinery is modulated by incretin hormones like GLP-1 and GIP, which amplify secretion through G protein-coupled receptor signaling (PubMed, PMID: 21864752). Dysregulation of this machinery is a hallmark of type 2 diabetes, where beta-cell compensation fails to meet insulin demand, and in hyperinsulinemic disorders (Nature Reviews Endocrinology, PMID: 33024244). Pharmacological intervention often targets specific components of this machinery, such as K_ATP channels (sulfonylureas) or GLP-1 receptors (incretin mimetics), to restore glycemic control (PubChem, CID: 3478).

Other names

Insulin secretory pathwayBeta-cell stimulus-secretion couplingGlucose-stimulated insulin secretion (GSIS) pathway

Drugs targeting this machinery typically act by closing ATP-sensitive potassium (K_ATP) channels to induce depolarization, activating glucagon-like peptide-1 (GLP-1) receptors to enhance cAMP-mediated signaling, or inhibiting dipeptidyl peptidase-4 (DPP-4) to increase endogenous incretin levels, all of which ultimately promote the exocytosis of insulin-containing granules (StatPearls, PMID: 30422492; PubMed, PMID: 21864752).